Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Hollandia2/3. fázis

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

A legfontosabb adatok

Ki végzi
Crinetics Pharmaceuticals Inc.
Hol
Groningen, Leiden és Rotterdam (Hollandia)Mind a 3 helyszín megnézéseMég 7 másik országban, 36 helyszínen
Állapot
Toborzás még nem indult
Fázis
2/3. fázis
Résztvevők
97 fő, tervezett
Kezdés
2026. okt. 31.
Várható befejezés
2031. márc. 31.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. október 12.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with ACTH-dependent Cushing's syndrome, a condition where too much ACTH hormone drives high cortisol. It tests atumelnant.

Életkor
≥18 to <75 years. At US sites, people ≥16 years of age may join.
Nem
Male or female.
A betegség stádiuma
Confirmed ACTH-dependent Cushing's syndrome. The ACTH source can be the pituitary, a tumor elsewhere (ectopic), or unknown. Shown by an abnormal dexamethasone suppression test and/or high late-night saliva cortisol in the past, or by tissue proof of an ACTH-producing tumor.
Korábbi kezelés
Current drugs for the condition must be stopped first: 2 weeks for ketoconazole, levoketoconazole or metyrapone; 4 weeks for osilodrostat, mifepristone or cabergoline; 8 weeks for pasireotide LAR. People who took atumelnant before, or ever used mitotane, cannot join. The open-label extension (Part C) is for people from Part A or B, or late screeners.
Biomarker vagy leletérték
Urine cortisol (mUFC) >1.3×ULN, checked by the central laboratory. Morning plasma ACTH >10 pg/mL.

A részvétel fő kizáró okai

  • Pituitary radiation therapy within 3 years of screening
  • High-risk pituitary tumor, such as a lesion within 2 mm of the optic chiasm, tumor growth within 1 year after surgery or radiation, or pituitary carcinoma
  • Expected need for brain surgery or radiation during the study
  • Major surgery or pituitary surgery within 1 month before screening
  • Life expectancy of less than 6 months, or an investigational drug within the past 60 days or 5 half-lives

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Part A and Part B Key Inclusion Criteria: 1. Male or female, ≥18 to <75 years of age at the time of signing the ICF. Participants≥16 years of age may be included at sites located in the US. Participants must have confirmed ADCS (pituitary, ectopic, or unknown source of excess ACTH after appropriate investigation) as evidenced by mUFC >1.3×ULN, confirmed by the central laboratory and available before Day 1 using adequate UFC samples as defined in the protocol
  • Part C Key Inclusion Criteria: 1. Participants from Part A or Part B who complete the 12-week Treatment Periods on study drug or are rescued due to hypercortisolism and who, in the Investigator’s opinion, may benefit from participation in the OLE
  • Part C Key Inclusion Criteria: 2. Late Screeners: When enrollment into Part B is closed, participants who were undergoing screening for Part B and who meet all Part B inclusion criteria may enroll directly into Part C. Participants may initiate Part C once all applicable eligibility criteria are confirmed
  • Part A and Part B Key Inclusion Criteria: 2. Documentation of either abnormal dexamethasone suppression test and/or elevated late-night salivary cortisol levels performed historically, or pathologic confirmation of an ACTH-producing tumor
  • Part A and Part B Key Inclusion Criteria: 3. Morning plasma ACTH >10 pg/mL
  • Part A and Part B Key Inclusion Criteria: 4. Washout of any current drug therapy for ADCS following Screening Visit 1. The following minimum washout periods must be completed before baseline efficacy assessments are performed: • 2 weeks: Ketoconazole, levoketoconazole, or metyrapone. • 4 weeks: Osilodrostat, mifepristone, or cabergoline. • 8 weeks: Pasireotide LAR. Participants who complete the Washout Period and whose mUFC is not >1.3×ULNmay repeat one set of triplicate UFC collections, if deemed safe and clinically appropriate in the Investigator’s opinion

Ki nem vehet részt

  • Part A and Part B Key Exclusion Criteria: 9. Participants who have previously taken atumelnant
  • Part A and Part B Key Exclusion Criteria: 7. Participants who received pituitary radiation therapy within 3 years of screening
  • Part A and Part B Key Exclusion Criteria: 10. Participants who will not benefit from chronic treatment with study drug or have a life expectancy of less than 6 months
  • Part A and Part B Key Exclusion Criteria: 11. Clinically significant concomitant disease considered by the Investigator likely to affect safe participation in the study
  • Part A and Part B Key Exclusion Criteria: 2. For medically untreated participants at Screening Visit 1, prior use of the following medications within the specified intervals prior to screening: - 2 weeks: Ketoconazole, levoketoconazole, or metyrapone. - 4 weeks: Osilodrostat, mifepristone, or cabergoline. - 8 weeks: Pasireotide LAR. Participants who have not completed the required washout periods are not eligible
  • Part A and Part B Key Exclusion Criteria: 3. Use of any investigational drug within the past 60 days or 5 half-lives (whichever is longer) prior to the first dose; or plan to use an investigational drug in another study
  • Part A and Part B Key Exclusion Criteria: 5. History of major surgery within 1 month prior to screening
  • Part A and Part B Key Exclusion Criteria: 6. Pituitary surgery within 1 month of screening
  • Part A and Part B Key Exclusion Criteria: 8. High-risk pituitary tumor pattern as defined by: - Current pituitary MRI findings of a lesion within 2 mm of the optic chiasm. - History of pituitary or ectopic tumor growth within 1 year after surgery(if performed) or radiation (unless it occurred during a period of medical therapy interruption) - Anticipated requirement for neurosurgical intervention or radiation therapy within the time course of the study. - Pituitary carcinoma
  • Part A and Part B Key Exclusion Criteria: 1. Known history of, or concern for hypersensitivity reaction to atumelnant or any of its excipients
  • Part A and Part B Key Exclusion Criteria: 4. Any history of mitotane use

Helyszínek itt: Hollandia

Még 7 másik országban, 36 helyszínen

  • Universitair Medisch Centrum GroningenGroningen, HollandiaToborzás még nem indult
  • Leids Universitair Medisch Centrum (LUMC)Leiden, HollandiaToborzás még nem indult
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the effect of atumelnant on mUFC at Week 12

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. október 12.